EHS
EHS

Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders

Amicus Therapeutics is expanding the focus its drug development work with the purchase of a portfolio of early-stage gene therapies targeting rare neurologic diseases, the company announced Thursday.

Two of the 10 gene therapies programs being acquired by Amicus have already entered human clinical trials as potential, one-time cures for different forms of Batten disease, an inherited and fatal neurodegenerative disease in children.

Read the rest…

Source link

EHS
Back to top button